JAMA vs NEJM: Which Medical Journal for Your Clinical Research?

JAMA (IF 55.0) and NEJM (IF 78.5) are the two most important clinical medical journals in the United States. Both accept fewer than 5% of submissions. Both will desk reject you within two weeks if your paper doesn't meet their bar. But they're not interchangeable. The editorial philosophies, scope preferences, and audience expectations differ in ways that matter for your submission strategy.

Head-to-Head

The Fundamental Editorial Difference

NEJM: The Clinical Trial Journal

NEJM's editorial heart is the large, well-designed clinical trial. If you ran a randomized controlled trial with 500+ patients and the result changes how doctors prescribe a drug, perform a procedure, or screen for a disease, NEJM is the natural first target.

NEJM wants:

• Practice-changing RCTs with definitive results
• Large prospective cohort studies with clear clinical implications
• Research that will be discussed at grand rounds worldwide the week it publishes
• Urgent findings (safety signals, pandemic data, breakthrough therapies)
• Clinical significance, not just statistical significance

NEJM's editorial voice is conservative and evidence-focused. They want the definitive study, not the preliminary one. If your trial has limitations that prevent definitive conclusions, NEJM may pass even if the data is interesting.

JAMA: The Broader Clinical Journal

JAMA has a significantly broader editorial appetite. While it publishes landmark clinical trials, JAMA also has a strong appetite for:

• Health policy research and healthcare systems analysis
• Medical education studies
• Population health and epidemiology
• Systematic reviews and meta-analyses (JAMA publishes more of these than NEJM)
• Public health implications of clinical findings
• Health equity and disparities research
• Research methods and evidence-based medicine

JAMA's editorial voice emphasizes readability and immediate applicability to patient care. The writing standard is the highest in medicine. JAMA's editorial team rewrites accepted papers more aggressively for clarity than any other top journal.

Decision Framework

The JAMA Network Advantage

One practical advantage of submitting to JAMA first: the JAMA Network. If JAMA desk rejects you, the editor may suggest a JAMA specialty journal. These are high-IF journals in their own right:

NEJM doesn't have an equivalent network. If NEJM rejects you, you're starting fresh at the next journal. JAMA's network gives you a soft landing where your editorial assessment may carry over.

Writing Style Differences

This matters more than most authors realize:

NEJM style: Dense, data-heavy, structured. Long methods sections. Tables with detailed statistical results. Written for physicians who want the complete evidentiary picture. The editor wants you to show your work.

JAMA style: Readable, accessible, narrative. JAMA editors will rewrite your paper to make it clearer. They want practicing physicians to read the paper at breakfast and know what to do differently with patients that morning. If your paper can't be explained in plain terms, JAMA's editors will try to help, but you should start that way.

Practical Submission Tips

For NEJM:

1. Lead with the clinical trial result. Don't bury the finding.
2. The abstract is everything. Many NEJM readers only read the abstract.
3. Pre-submission inquiry is available and worth using.
4. If your trial is registered (it should be), include the ClinicalTrials.gov number prominently.
5. CONSORT checklist compliance is mandatory for RCTs.

For JAMA:

1. Write for clarity. Assume your reader is a busy internist with 5 minutes.
2. Include a "Key Points" box: Question, Findings, Meaning. This is required and editors evaluate it seriously.
3. The cover letter should explain what this adds to existing evidence.
4. If you're submitting a meta-analysis, follow PRISMA guidelines precisely.
5. Patient/public health implications should be explicit, not implied.

What If Both Reject You?

At ~5% acceptance each, rejection from both is likely. Your paper was still strong enough to submit to the top tier, which means it's competitive at:

The Strategic Sequence

If you're targeting the Big 4 medical journals, here's a common strategic sequence:

1. NEJM if your study is a definitive clinical trial
2. JAMA if it's broader clinical or policy-relevant
3. Lancet if it has global health significance
4. BMJ if it's public health, primary care, or needs open access

Don't submit to all four simultaneously. Pick one, wait for a decision (usually 2-3 weeks), then move to the next.

More Resources

• JAMA journal guide
• NEJM journal guide
• NEJM under review - what to expect during NEJM review
• BMJ acceptance rate
• Acceptance rates across 50+ journals
• Review timelines compared